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Edited by Jesus AvilaAbstract It has been suggested that transthyretin (TTR) is in-
volved in preventing A-Beta ﬁbrillization in Alzheimers disease
(AD). Here, we characterized the TTR/A-Beta interaction by
competition binding assays. TTR binds to diﬀerent A-Beta pep-
tide species: soluble (Kd, 28 nM), oligomers and ﬁbrils; diverse
TTR variants bind diﬀerentially to A-Beta. Transmission elec-
tron microscopy (TEM) analysis demonstrated that TTR is
capable of interfering with A-Beta ﬁbrillization by both inhibit-
ing and disrupting ﬁbril formation. Co-incubation of the two
molecules resulted in the abolishment of A-Beta toxicity. Our re-
sults conﬁrmed TTR as an A-Beta ligand and indicated the inhi-
bition/disruption of A-Beta ﬁbrils as a possible mechanism
underlying the protective role of TTR in AD.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Alzheimers disease (AD) presently aﬀects 20–30 million
individuals worldwide and accounts for most cases of dementia
that are diagnosed after the age of 60. Histopathologically, this
disease is characterized by two lesions: senile or neuritic pla-
ques and neuroﬁbrillary tangles (NFTs) [1]. Neuritic plaques
are mainly constituted by extracellular deposits of the 40-
and 42-amino acid beta-amyloid (A-Beta) peptides. The pep-
tide in these plaques is in the form of insoluble amyloid ﬁbrils
mixed with a poorly deﬁned array of non-ﬁbrillar forms of the
peptide [2]. A-Beta, a 37–43 amino acid peptide with 4 kDa, is
produced by proteolytic cleavage of a large transmembrane
precursor, the amyloid precursor protein (APP) [3]. Several
molecules were identiﬁed and suggested as A-Beta carriers
[4,5]. Among them, TTR has recently received a large attention
[6–9]. TTR is a homotetrameric 55 kDa protein producedAbbreviations: AD, Alzheimers disease; WT TTR, wild-type trans-
thyretin; V30M TTR, transthyretin with a valine substitute by a
methionine at position 30; L55P TTR, transthyretin with a leucine
substitute by a praline at position 55; Y78F TTR, transthyretin with a
tyrosine substituted by a phenylalanine at position 78; T119M TTR,
transthyretin with a threonine substituted by a methionine at position
119
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doi:10.1016/j.febslet.2008.02.034mainly in the liver and in the choroid plexus of the brain
[10] that is responsible for thyroid hormone and retinol trans-
port [11]. Over 100 TTR mutations have been identiﬁed and
associated with TTR related amyloid deposition in familial
amyloidotic polyneuropathy, aﬀecting the peripheral nervous
system.
Schwarzman and co-workers used human cerebrospinal
ﬂuid (CSF) incubated with synthetic A-Beta (1–40) to identify
the interacting proteins and to evaluate the peptide aggrega-
tion levels [4]. The authors concluded that TTR was the major
A-Beta binding protein in the CSF; a decrease in the aggrega-
tion state of the peptide as well as in its toxicity in the presence
of TTR was also observed [4,12]. The sequestration hypothesis
was put forward: normally produced A-Beta is sequestered by
certain extracellular proteins, thereby preventing amyloid for-
mation and A-Beta cytotoxicity; formation of amyloid and the
consequent toxicity occurs when sequestration fails [12]. In vivo
experiments were also performed in order to investigate the
protective eﬀect of TTR. In Caenorhabditis elegans expressing
human A-Beta (1–42), TTR rescued the neurodegeneration
triggered by the toxic peptide [13]. Studies in transgenic mice
overexpressing mutant APP revealed slow disease progression
and lack of neurodegeneration attributed to TTR expression
[7]. In the absence of TTR, A-Beta deposition was accelerated
[9].
The discussion on TTR/A-Beta interaction and consequent
inhibition of aggregation and toxicity reduction raised the
hypothesis that mutations in the TTR gene or conformational
changes in the protein induced by aging, could aﬀect the
sequestration properties. However, no mutations in the TTR
gene have been found in AD patients [14].
To summarize, TTR may prove to be a useful therapeutic
agent capable of preventing or retarding cerebral amyloid pla-
que formation in AD. Nevertheless, the precise mechanism by
which TTR acts against the amyloidogenicity and toxicity of
the A-Beta peptide is unknown and thus further investigation
is necessary.2. Materials and methods
2.1. Production of A-Beta species
A-Beta peptide (1–42) was purchased from BioSource, dissolved in
HFIP and kept at room temperature for 1–2 h. HFIP was then re-
moved under a stream of nitrogen until a clear ﬁlm remained in the
Eppendorf tube. The residue was then dissolved in DMSO at 2 mM
concentration. Soluble A-Beta was prepared by instantly diluting the
peptide in the appropriate buﬀer and used immediately for competition
binding assays; to prepare oligomers, A-Beta peptide was diluted toblished by Elsevier B.V. All rights reserved.
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the peptide was incubated at 37 C for 8 days; samples were then ana-
lyzed by transmission electron microscopy (TEM).
2.2. TTR production and puriﬁcation
Recombinant TTRs were produced in a bacterial expression system
using Escherichia coli BL21 [15] and puriﬁed as previously described
[16]. Brieﬂy, after growing the bacteria, the protein was isolated and
puriﬁed by preparative gel electrophoresis after ion-exchange chroma-
tography. Protein concentration was determined using the Lowry
method [17].
2.3. Competition binding assays
Recombinant wild-type transthyretin (WT TTR) was iodinated with
Na125I (NEN) using the Iodogen (Sigma) method following the sup-
pliers instructions. The reaction mixture was subsequently desalted
by Sephadex G50 gel ﬁltration. 96 well plates (Maxisorp, Nunc) were
coated with soluble, oligomeric or ﬁbrillar A-Beta peptide prepared as
described (5 lg/well) in coating buﬀer (0.1 M bicarbonate/carbonate
buﬀer, pH 9.6) and incubated overnight at 4 C. Unoccupied sites were
blocked by incubation with 5% non-fat dried milk in PBS for 2 h at
37 C. For competition studies, a constant amount of 125I-labelled
WT TTR was added to each well alone or in the presence of the indi-
cated molar excess of unlabelled competitors. Speciﬁc binding was de-
ﬁned as that observed with 125I-labelled protein alone minus 125I-
labelled protein in the presence of 100-fold molar excess unlabelled
protein. Kd assays were performed as described elsewhere [18]. Binding
data were ﬁt to a one-site model and analyzed by the method of Klotz
and Hunston using non-linear regression analysis with the Prism pro-
gram (GraphPad Software Inc.). Results are shown as percent of max-
imal binding ± S.D. and are representative of a minimum of two
independent experiments.
T4 binding competition assays were based on a gel ﬁltration proce-
dure as previously described [19]. Brieﬂy, 50 ll of a diluted sample
(30 nM TTR) was incubated with 50 ll of either cold T4 solutions or
A-Beta peptide (1–42) solutions of variable concentrations ranging
from 0 to 1000 nM and with a constant amount of labeled 125I-T4
(50,000 cpm). This solution was counted in a gamma spectrometer
and incubated at 4 C overnight. Protein bound 125I-T4 and free 125I
-T4 were separated by gel ﬁltration through a 1 ml BioGel P6DG
(Bio-Rad) column. The bound fraction was eluted while free T4 was re-
tained on the BioGel matrix. The eluate containing the bound T4 was
collected and counted. Bound T4 was expressed as percentage of total
T4 added. Each assay was performed in triplicate. Analysis of the bind-
ing data was performed with the GraphPad Prism program (version
2.0, San Diego, CA).2.4. Inﬂuence of TTR in A-Beta aggregation and ﬁbril disruption
A-Beta peptide 100 lM, prepared as described, was incubated with
diﬀerent TTR variants (10 lM), and incubated at 37 C for diﬀerent
periods of time. Alternatively, A-Beta 100 lM was incubated alone
at 37 C for 8 days and then 10 lM TTR, either WT or L55P, was
added and further incubated at 37 C for the desired time. Samples
were analyzed by TEM.2.5. Transmission electron microscopy
For visualization by TEM, sample aliquots were absorbed to glow-
discharged, carbon-coated collodion ﬁlm supported on 200-mesh cop-
per grids, and negatively stained with 1% uranyl acetate. The grids
were exhaustively visualized with a Zeiss microscope (model
EM10C), operated at 60 kV.2.6. Cell culture and caspase-3 assay
SH-SY5Y cells (human neuroblastoma cell line) were propagated in
25-cm2 ﬂasks and maintained at 37 C in a 95% humidiﬁed atmosphere
and 5% CO2. Cells were grown in Dulbeccos minimal essential med-
ium supplemented with 10% fetal bovine serum (Gibco BRL). Activa-
tion of caspase-3 was measured using the CaspACE ﬂuorimetric 96-
well plate assay system (Sigma), following the manufacturers instruc-
tions. Brieﬂy, 10 lM A-Beta peptide pre-incubated for 48 h in F12
media (Gibco BRL) with or without 2 lM TTR at 4 C with shaking,
were added to 80% conﬂuent cells in Dulbeccos minimal essential
medium with 1% fetal bovine serum, and further incubated for 48 h,at 37 C. Subsequently, each well was trypsinized and the cell pellet
was lysed in 100 ll of hypotonic lysis buﬀer (Sigma). Forty microlitres
of each cell lysate was used in duplicates for determination of caspase-3
activation. The remaining cell lysate was used to measure total cellular
protein concentration with the Bio-Rad protein assay kit (Bio-Rad),
using BSA as standard. Values shown are the mean of duplicates
and the experiment was performed three times. Comparison between
groups was made using the Students t-test. A P value of less than
0.05 was considered statistically signiﬁcant.3. Results
3.1. Assessment of WT TTR binding to diﬀerent species of
A-Beta
It has been previously reported that TTR acts as an A-Beta
carrier [4,6]. To further characterize this interaction we per-
formed competition binding assays using soluble A-Beta pep-
tide (1–42) and recombinant 125I-TTR. Using this technique
we were able not only to conﬁrm the interaction between the
two molecules but also to determine a Kd of 28 ± 5 nM
(Fig. 1A). We next produced A-Beta amyloidogenic species,
oligomers and ﬁbrils, upon incubation of the peptide at 4 C
or 37 C, respectively, for diﬀerent periods of time. Oligomers
appeared as short and thin protoﬁlaments together with round
particles, 4–5 nm wide (Fig. 1 C, upper panel), while A-Beta
incubated at 37 C for 8 days formed long ﬁbrils, 10–13 nm
of diameter (Fig. 1C, lower panel). These species were then as-
sessed for binding to TTR and results showed that they also
bind to TTR (Fig. 1B), with aﬃnities similar to the soluble
counterpart.3.2. Interaction of diﬀerent TTR variants with A-Beta
We next assessed the ability of diﬀerent TTR mutations,
amyloidogenic (transthyretin with a valine substitute by a
methionine at position 30 (V30M TTR), transthyretin with a
leucine substitute by a proline at position 55 (L55P TTR)
and transthyretin with a tyrosine substituted by a phenylala-
nine at position 78 (Y78F TTR)) and non-amyloidogenic
(transthyretin with a threonine substituted by a methionine
at position 119 (T119M TTR)) to bind the A-Beta peptide,
using the same approach as above. The competition binding
assays allow us to conclude that the diverse variants bind dif-
ferently to the peptide in the following manner: T119M
TTR >WT > V30M P Y78F > L55P, as displayed in Fig. 2.
These results suggest an inverse relation between the amyloido-
genic potential of TTR and aﬃnity to the peptide. Table 1 dis-
plays the relative aﬃnities found for the diﬀerent TTR variants
when binding to soluble A-Beta.
We also investigated if binding of A-Beta peptide to TTR
involved the T4 binding channel by performing competition
assays with 125I-T4. Our results showed no competition
between T4 and A-Beta peptide towards binding to TTR (data
not shown).
3.3. Eﬀect of TTR in A-Beta ﬁbrillization
To ascertain if TTR binding to A-Beta peptide has any
impact on the ﬁbrillization of the peptide, we performed
ultrastructural analysis of co-incubated WT TTR and soluble
A-Beta preparations; visualization of the samples by TEM re-
vealed a decrease in the number and length of the ﬁbrils when
compared to preparations of A-Beta incubated alone (Fig. 3,
middle and left panels, respectively), indicating that TTR
Fig. 1. Characterization of TTR and A-Beta interaction. (A) Binding of 125I-WT TTR to soluble A-Beta peptide; a Kd of 28 ± 5 nM was calculated
as described in Section 2. (B) Binding of 125I-WT TTR to diﬀerent amyloidogenic species of A-Beta peptide: soluble (A-Beta soluble), oligomers
formed at 4 C for 48 h (oligomers 48 h) and ﬁbrils formed at 37 C for 8 days (ﬁbrils 8d) demonstrating similar aﬃnities. (C) Morphologic
characterization assessed by TEM of A-Beta oligomeric (upper panel) and ﬁbrillar (lower panel) species. Scale bar = 200 nm.
Fig. 2. Competition binding assays with TTR variants. Displacement
curves of 125I-WT TTR from soluble A-Beta by diﬀerent TTR variants
(WT TTR, V30M, Y78F, L55P and T119M).
Table 1
Binding aﬃnity of diﬀerent TTR variants towards A-Beta, relative to
the WT counterpart
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the experiment WT TTR does not aggregate [20]. Extended
incubations at 37 C for at least 7 days revealed that TTR
did not lose the inhibitory ability, resulting in a more pro-
nounced eﬀect as only small oligomers were observable under
the microscope. Control samples of WT TTR alone were also
prepared and analysed; no ﬁbrils or aggregates were seen (data
not shown) but only round particles representing the native
protein.
We next studied the eﬀect of the TTR variants, previously
shown to bind the peptide, on A-Beta ﬁbrillization; L55P
and T119M were chosen due to their lowest and highest bind-
ing capacities, respectively. The peptide was incubated with or
without the TTR variant, at 37 C, and the samples were ana-
lysed at diﬀerent stages (day 1, day 5 and day 7), similarly to
the study performed with WT TTR. In Fig. 3, right panels,
the eﬀects of L55P TTR on A-Beta ﬁbrils are noticeable,
revealing that this variant retained the ability to inhibit A-Beta
ﬁbril formation; comparable data was gathered using T119M
TTR (not shown) and thus, no signiﬁcant diﬀerences were
found between TTR variants and the WT counterpart in their
capacity to inhibit A-Beta ﬁbril formation. The discrepancy
observed between binding and eﬀect on ﬁbrillization for the
diﬀerent TTR variants used, may reﬂect that diﬀerent mecha-
nisms are implicated in the two processes; it can also indicate
a limitation of the technique used since TEM is not a quanti-
tative approach and therefore may fail to detect the diﬀerences.
Fig. 3. Inﬂuence of TTR in A-Beta ﬁbrillization. A-Beta peptide was incubated with or without TTR during diﬀerent periods of time and analyzed
by TEM at days 1, 5 and 7. The data revealed a decrease in the number and the length of ﬁbrils when the peptide was co-incubated with WT TTR
(middle panels) when compared with A-Beta incubated alone (left panels). No signiﬁcant diﬀerences were detected among the TTR variants tested, as
shown here for L55P TTR (right panels), thus showing inhibition of A-Beta ﬁbrillization. Scale bar = 100 nm.
Fig. 4. Disruption of A-Beta ﬁbrils by TTR. A-Beta ﬁbrils were grown for 8 days at 37 C as described in Section 2; then TTR was added and further
incubated at 37 C and analyzed at diﬀerent time points by TEM. A-Beta alone generated long ﬁbrils 10–13 nm wide (A), whereas addition of WT
TTR resulted in shorter ﬁbrils after 2 days of co-incubation (B); continued incubation at 37 C resulted in even shorter ﬁbrils (C, 4 days) and in small
aggregates and oligomers (D, 14 days). Co-incubation of L55P TTR with A-Beta peptide for 4 days at 37 C indicated that this variant retained the
disrupter activity (E). Scale bar = 100 nm.
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formed ﬁbrils where TTR, either WT or L55P, was addedand further incubated at 37 C. Surprisingly and contrarily
to a previous report [12], our data indicated that TTR was also
Fig. 5. Caspase-3 activation in cell culture. A-Beta with or without TTR or TTR alone incubated at 4 C for 48 h were then added to SH-5YSY
cultured cells and further incubated for another 48 h at 37 C. A-Beta was used at a ﬁnal concentration of 10 lM and TTR at 2 lM. Signiﬁcant
caspase-3 activation was observed in the presence of A-Beta (A-Beta oligomers), when compared to non-treated (NT) and TTR-treated (WT TTR)
cells; toxicity of A-Beta was prevented by pre-incubating the peptide with TTR (A-Beta + WT TTR). *P < 0.05.
940 R. Costa et al. / FEBS Letters 582 (2008) 936–942able to disrupt A-Beta ﬁbrils as shorter ﬁbrils were observed 2
days after the addition of WT TTR, as depicted in Fig. 4B,
when compared with control samples containing A-Beta incu-
bated alone (Fig. 4A); extended incubations for 4 and 14 days
resulted in even shorter ﬁbrils (Fig. 4C) and small aggregates
and oligomers (Fig. 4D), respectively. TTR alone was also
incubated for the same time periods and observed under the
electron microscope showing no ﬁbrils or aggregates; again
only round particles similar to the native protein were ob-
served (data not shown). No signiﬁcant diﬀerences were found
between TTR WT and L55P, the most amyloidogenic TTR
variant used in their ability do disaggregate A-Beta peptide ﬁ-
brils (Fig. 4E). Taken together, our results indicate TTR not
only as an A-Beta ﬁbril inhibitor but also as a ﬁbril disrupter.
3.4. TTR abolishes A-Beta toxicity in cell culture
A-Beta peptide (1–42) is toxic to cells and leads to apoptosis
and cellular death; previous works performed in vitro and
in vivo demonstrated that the oligomeric form of the peptide
has the highest toxicity [21]. Here we tested the hypothesis that
TTR could protect against this neurotoxicity. We measured
caspase-3 activity occurring in SH-SY5Y cells incubated with
TTR pre-incubated with A-Beta 1–42, TTR alone or A-Beta
alone (Fig. 5). In the latter, signiﬁcant caspase-3 activation
was observed, in opposition to cells incubated with TTR alone
or A-Beta pre-incubated with TTR which presented levels of
caspase-3 activation similar to the non-treated control cells.
Therefore, TTR abolishes A-Beta oligomers toxicity.4. Discussion
A-Beta peptide deposition in the brain is the biochemical
hallmark in AD and although APP processing and A-Beta
generation have been intensely investigated, the reasons why
the peptide deposits extracellularly in the brain are not com-
pletely understood. TTR has been suggested as an A-Beta car-
rier [12,22] and attempts to relate TTR/A-Beta levels in CSF
and AD have been made [23,24]. Previous in vitro studies
established diﬀerences between TTR variants in their binding
ability towards the A-Beta peptide [25].
In the present work, the WT TTR/A-Beta peptide interac-
tion was further investigated and the respective Kd determinedas 28 ± 5 nM. We also observed that TTR interacted with
other forms of A-Beta, namely oligomers and ﬁbrils with sim-
ilar aﬃnities (Fig. 1B). TTR interaction with A-Beta peptide
in vivo in CSF refers to the soluble form of the peptide with
consequent rescue of A-Beta aggregation. Thus, binding of
TTR to aggregated forms of A-Beta peptide (oligomers and ﬁ-
brils) with similar strengths was unexpected, since in these spe-
cies, especially in the ﬁbrils, the availability of the epitopes
should be lower than in the soluble counterpart. Other authors
have observed binding of TTR to aggregated forms of the pep-
tide [26]. In their work, binding of TTR to A-Beta (1–40) was
investigated and results indicated that TTR suppressed growth
of A-Beta aggregates but did not inhibit the initial assembly.
These authors also hypothesize that TTR binds preferentially
to growing A-Beta rather than to soluble non-aggregated
peptide and estimated an association constant of 2300 ±
100 M1. Although A-Beta aggregates were visible upon
TTR incubation, inhibition of the initial A-Beta assembly can-
not be ruled out due to the great tendency for aggregation of
the synthetic peptide. As mentioned above we observed similar
binding aﬃnities for all the A-Beta species tested, and whereas
Liu and co-workers did not speciﬁcally tested binding to ma-
ture ﬁbrils, we used A-Beta (1–42) which can account for the
diﬀerences observed, including a stronger interaction (Kd
28 ± 5 nM).
The inﬂuence of TTR mutations, such as T119M, Y78F,
V30M and L55P, in the binding to A-Beta was also investi-
gated. TTR variants bound diﬀerently to A-Beta in the
following order: T119M >WT > V30M P Y78F > L55P,
suggesting that the ability to rescue the peptide is diﬀerent be-
tween them, with possible implications in A-Beta deposition in
the brain. Our observation suggests an inverse relation
between the amyloidogenic potential of TTR and aﬃnity to
A-Beta peptide, i.e. a direct relation with protein stability.
X-ray diﬀraction studies of L55P TTR suggested this variant
as an amyloidogenic intermediate in the process of TTR ﬁbril
formation. The mutation leads to the disruption of the D
strand due to the disturbance of the hydrogen bonds between
strands D and A, thus residues 54–56 are part of a long surface
loop that connects strands C and E [27]. This variant, the less
stable and most amyloidogenic among the tested ones, showed
the lowest aﬃnity to the peptide, whereas the anti-amyloido-
genic one, T119M, showed the highest aﬃnity, indicating that
R. Costa et al. / FEBS Letters 582 (2008) 936–942 941conformational molecular changes are important to the bind-
ing, and therefore, the D strand region is relevant in binding
to A-Beta. Biochemical studies also showed that several amy-
loidogenic TTR mutations alter the protein stability leading to
tetramer dissociation and favoring an abnormal monomeric
structure, that polymerizes into several intermediates and ﬁnal-
ly into amyloid ﬁbrils [28]. T119M TTR is a non-amyloido-
genic variant previously described to attenuate the symptoms
in carriers of the V30M mutation. This fact may be related
to increased stability, since the T119M mutation presents high-
er resistance to dissociation into monomers than WT TTR
[29]. T119M TTR crystal structure showed new H-bonds with-
in each monomer and monomer–monomer inter-subunit con-
tacts (S117–S117 and M119–Y114), resulting in increased
protein stability, possibly leading to the protective eﬀect of
the TTR V30M/T119M [28]. The mutation is located in the
H strand and participates in the binding to T4, resulting in in-
creased aﬃnity for the hormone. Competition binding assays
using labeled T4 showed no competition with A-Beta peptide
for binding to TTR, indicating that the peptide binds TTR
in a location other than the T4 binding channel.
Ultrastructural studies indicated that besides inhibiting A-
Beta oligomerization, TTR also disrupted A-Beta ﬁbrils, a
contradictory fact to what was observed by Schwarzman and
Goldgaber [12] that only detected the inhibitory eﬀect. Our re-
sults are in good agreement with the binding data since TTR
binds to soluble, oligomeric and ﬁbrillar A-Beta with compara-
ble aﬃnities. Altogether, our ﬁndings open new perspectives
on the role of TTR in AD. The total pool of A-Beta peptide
depends not only of its production, by proteolytic processing
of the precursor protein, but also of its removal. While there
is some information elucidating the enzymes and pathways
participating in peptide production, much less is known
regarding A-Beta catabolism [30]. Our results have implicated
TTR as an agent able to participate in the catabolism of the
peptide, since it can interact with A-Beta contributing not only
to maintenance of soluble A-Beta levels within normal range in
the CSF but also to removal of deposited A-Beta in amyloid
plaques, in case of imbalance and disease. The literature re-
ports on both the localization of TTR within senile plaques
[8,31] and on the absence of TTR localized in plaques
[32,33], in AD either in clinical samples and animal models.
No correlation was found between the degree of inhibition/
disruption of A-Beta ﬁbrillogenesis and TTR variants, since all
mutations tested displayed similar inhibitory/disrupter activi-
ties, under the conditions tested. These results suggest that
binding and inhibition/disruption of ﬁbril formation are not
necessarily related events, and that diﬀerent regions of the
TTR molecule might be involved in the two processes.
Finally, we addressed the question whether this mechanism
of inhibition of A-Beta aggregation and/or ﬁbril disruption
could confer protection to cells. Caspase-3 signiﬁcantly acti-
vated in cells treated with A-Beta oligomers was abolished in
cells treated with A-Beta co-incubated with TTR, thus demon-
strating TTR protective role against A-Beta toxicity. A-Beta
toxicity to neuronal cells can be triggered by diﬀerent mecha-
nisms such as interaction with the serpin-enzyme complex
(SEC) receptor, ion pore formation, receptor for advanced gly-
cation end products (RAGE) engagement, oxidative stress
damage [34] and internalization via pinocytosis [35]. Protection
against A-Beta toxicity by TTR may encompass one or more
of such mechanisms.Future work should aim at:
– Identifying the TTR regions involved in binding to A-Beta.
– Understanding the diﬀerences between TTR binding to A-
Beta and TTR inhibitory/disrupter activities thus perceiving
the results observed with TTR variants.
– Unravel the mechanism underlying the protective role of
TTR against A-Beta toxicity.
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